Kornimate/medical-research-clean huggingface dataset:
effect of oxyflower® gel as a coadjuvant in pericoronitis treatment

Conditions: Pericoronitis

Summary: the objective of this study is to evaluate the clinical effect and the impact on the quality of life of the coadjuvant treatment with oxyflower® gel in cases of pericoronitis in lower third molar, compared to chlorhexidine gel and placebo gel.

this study consist of 51 participants diagnosed with pericoronitis who received coadjuvant treatment with gel. the participants were submitted to emergency treatment, with local debridement and irrigation with saline solution followed by topical application of the randomized gel: oxyflower®, chlorhexidine, or placebo gel. in cases of pericoronitis with systemic signs / symptoms, such as fever, malaise and lymphadenopathy, systemic antibiotic therapy was prescribed one hour before debridement, lasting seven days. all participants received oral hygiene guidelines and were instructed to apply the same gel twice daily for one week . after 30 days, it was performed tooth removal for cases in which there is not enough space for dental eruption; or distal wedge surgery when there is space for dental eruption with excessive gingiva in the distal. it was evaluated as outcomes: pain, quality of life, depth of probing, level of bone crest in the distal of second molar, buccal opening and extent of edema / erythema. a comparative analysis was performed between the groups, before and after treatment.

Eligibility criteria:
inclusion criteria: * signs / symptoms of pericoronitis with * spontaneous pain * asa i or ii * consent to participate exclusion criteria: * periodontal status level iv * smokers * antibiotic therapy in the last 2 months

Keywords: quality of life pericoronitis phytotherapy
feasibility study of sentinel navigation surgery after non-curative endoscopic resection

Conditions: Sentinel Lymph Node; Early Gastric Cancer

Summary: purpose: to prove the feasibility of sentinel node navigation surgery (snns) in early gastric cancer patients with the risk of lymph node metastasis after endoscopic resection and preparation of multicenter phase 3 trial of stomach preserving surgery in these patients. contents: the number of enrollment is 247 patients. the patients underwent endoscopic resection for early gastric cancer, and the tumor was defined to be out of indication for endoscopic resection pathologically. so, additional gastrectomy is recommended for them. the investigators will enroll patients who agree this study. after general anesthesia, tc99m-phytate with indocyanine green will be injected with endoscopy. then sentinel basin will be detected using gamma probe and laparoscopic basin dissection will be done. sentinel lymph node will be identify in back table dissection, and patients will undergo conventional gastrectomy. detection rate and false negative rate will be evaluated by pathological review.

sentinel basin dissection method 1. endoscopic tracer injection after general anesthesia 2. tracer : tc99m-phytate 3cc and indocyanine green 3cc mix --\> injection of the probe (1cc/site, 4 sites) around endoscopic submucosal dissection ulcer scar 3. sentinel basin identification with laparoscopic probe 4. dissection of the sentinel basin 5. sentinel node dissection at back table 6. conventional laparoscopic gastrectomy

Eligibility criteria:
inclusion criteria: * no limitation for age if the patient is available for gastrectomy * patient who underwent endoscopic submucosal dissection and the tumor was defined as out of indication. the expanded criteria for endoscopic resection are as follows * criterion i: intramucosal tumor without ulcerative findings and of differentiated type with size \> 2 cm * criterion ii: intramucosal tumor with ulcerative findings and of differentiated type with size ≤ 3 cm * criterion iii: intramucosal tumor without ulcerative findings and of undifferentiated type with size \< 2 cm * criterion iv, submucosal invasion \< 500 mm and of differentiated type with size ≤ 3 cm) * eastern cooperative oncology group (ecog) performance scale 0 or 1 exclusion criteria: * inoperative due to severe cardiovascular or pulmonary disease * pregnant * patients who had previous gastric surgery * patients who had previous upper abdomen surgery except cholecystectomy, or radiation therapy on upper abdomen, or hypersensitivity to any medicine

Keywords: sentinel lymph node early gastric cancer non-curative endoscopic resection
desensitization of human mast cells: mechanisms and potential utility for preventing anaphylaxis

Conditions: Anaphylaxis

Summary: this is an open-label, single-center study of whether oral penicillin desensitization of healthy sensitive subjects results in allergen cross-desensitization of mast cells by skin testing and desensitization of peripheral blood basophils. the primary endpoint(s) will be pc3 prick skin test values to penicillin, aeroallergen(s) and codeine. secondary endpoints will be levels of syk in purified basophils determined by flow cytometry (mean fluorescence intensity) and basophil degranulation (% tryptase release) to anti-fcåri and to calcium ionophore.


Eligibility criteria:
inclusion criteria: * written informed consent obtained. * male, or non-pregnant female, 18-45 years of age who are in good health. * clinical history of a penicillin allergy consisting of an immediate hyper- sensitivity reaction such as anaphylaxis, urticaria/angioedema or broncho- spasm, and a positive skin prick test to penicillin g. * positive skin test to at least one aeroallergen to indicate sensitivity, but clinical disease (allergic rhinitis) is not necessary. exclusion criteria: * dermatographism or severe dermatologic condition, such as advanced eczema or psoriasis, that will not allow an adequate uninvolved area for skin testing. * negative skin tests to penicillin g or to all aeroallergens test. * pregnancy. * antihistamine medications taken within one week of testing; systemic steroids, b-blockers or ace -inhibitors taken over the previous month; omalizumab therapy at any time; those receiving or who have received immunotherapy; and those who have been desensitized to any drug within 6 months. * allergic reaction to a b-lactam antibiotic within 1 month. * current asthma; significant pulmonary, cardiovascular, renal, hepatobiliary or neurological diseases, or another disease process that the investigator feel would put the subject at risk of an adverse event. * mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements. * inability or unwillingness of a participant to give written informed consent.

Keywords: penicillin allergy prevention anaphylaxis clinically proven history of penicillin allergy preventing anaphylaxis
central china rosai-dorfman disease registry

Conditions: Rosai-Dorfman Disease; Langerhans Cell Histiocytosis

Summary: this is a research study among patients with rosai-dorfman disease.

rosai-dorfman disease is a rare disorder characterized by overproduction (proliferation) and accumulation of a specific type of white blood cell (histiocyte) in the lymph nodes of the body (lymphadenopathy), most often those of the neck (cervical lymphadenopathy). in some cases, abnormal accumulation of histiocytes may occur in other areas of the body besides the lymph nodes (extranodal). these areas include the skin, central nervous system, kidney, and digestive tract. the symptoms and physical findings associated with rosai-dorfman disease vary depending upon the specific areas of the body that are affected. the disorder predominantly affects mainly adolescents or young adults. the exact cause of rosa dorfman disease is unknown. the purpose of this research study is to learn the prevalence , therapies and long term prognosis of rosa dorfman disease.

Eligibility criteria:
inclusion criteria: diagnosis of a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings. all participants will undergo standard of care mra, cta or imaging examination. exclusion criteria: known intracranial involvement of histiocytosis (including dura, leptomeninges and brain parenchyma) prior stroke or intracranial hemorrhage other (non-histiocytic) intracranial neoplasm or neurological disorder deemed by the pi or co-pi to confound neuroimaging studies (e.g., demyelinating disease) existing diagnosis of a psychiatric disorder or untreated mood disturbance existing diagnosis of a neurodegenerative disease, such as alzheimer's disease chronic or daily excessive alcohol consumption as determined by the pi. history of chronic use of corticosteroids, defined as continuous treatment for six months or longer at any time in the past history of severe claustrophobia or other contraindications to patient soc brain mri prior intravenous cytarabine or cladribine other current or prior treatments (e.g., high-dose chemotherapy for a different cancer) deemed by the pi or co-pi to confound imaging studies or cognitive performance
determination of adipocytokine in synovial fluid of osteoarthritis patients

Conditions: Osteoarthritis

Summary: the purpose of this study is to determine the concentration of different adipocytokine (adiponectin, leptin, resistin, visfatin, osteopontin) and an inflammation classic markers as interleukine 1 beta, tumor necrosis alfa, interleukine 6 and high sensibility reactive c protein in the synovial fluid of knee osteoarthritis patients, and compare with the inflammation detected with ultrasonography evaluation of the joint. in last years, some studies appeared focusing on the role of adipocytokines in osteoarthritis and they correlated adipocytokines with cartilage degradation and x-ray degree; in our study we will focused in the importance of adipocytokines in the inflammatory changes more than in joint destruction.


Eligibility criteria:
inclusion criteria: * aged 50 to 81 * primary osteoarthritis of the knee * synovial effusion in examination * patient who have the results in our database exclusion criteria: * any other rheumatic conditions as rheumatoid arthritis or another inflammatory disease * secondary knee osteoarthritis * history of knee surgery * any conditions that at investigator criteria exclude the patient from study procedures

Keywords: adipocytokines osteoarthritis inflammation ultrasonography
mre for diagnosis of pancreatic masses

Conditions: Pancreatic Neoplasm; Magnetic Resonance Imaging

Summary: pancreatic ductal adenocarcinoma (pdac) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. the extracellular matrix (ecm) surrounding pdac often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of pdac. high order three-dimensional mr elastography (3d-mre) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. however, there are no reports about the application of mre imaging biomarkers to predict the prognosis of pdac at home and abroad.

pancreatic ductal adenocarcinoma (pdac) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. the extracellular matrix (ecm) surrounding pdac often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of pdac. although interstitial composition is considered a double-edged sword, influencing cancer biological progression and modification in multiple complex ways, experimental studies consistently demonstrate that hardening of ecm in pdac accelerates pdac progression and is significantly associated with shorter survival. if investigators can noninvasively detect the mechanical properties (hardness) of human pdac before treatment, it will be helpful to describe the biological characteristics of tumors, predict the prognosis of patients, and choose the right clinical treatment decision. high order three-dimensional mr elastography (3d-mre) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. however, there are no reports about the application of mre imaging biomarkers to predict the prognosis of pdac at home and abroad.

Eligibility criteria:
inclusion criteria: 1. granting of written informed consent 2. age ≥18 years 3. no history of extrapancreatic malignancy 4. no preoperative biliary drainage 5. definitive histologic evidence of pdac in excisional biopsy 6. with no less than three months of postoperative mortality or six months of follow- up exclusion criteria: 1. inability to re-review of tissue specimens 2. unacceptable estimates of mre parameters, specifically invalid wave data during postprocessing, inconsistent breath-holdings, intolerable pain, and mre hardware disconnection 3. tumor diameters \<1.0 cm 4. withdrawal/dropout during follow-up

Keywords: pancreatic cancer, solid pancreatic mass magnetic resonance elastography
corticosteroid reduction in copd

Conditions: Lung Diseases, Obstructive; Blood Eosinophil Count; Glucocorticoids; COPD; Pulmonary Disease, Chronic Obstructive

Summary: this study explores whether patients hospitalized with chronic obstructive pulmonary disease (copd) exacerbation may have fewer days with prednisolone and with the same treatment effect by controlling the treatment by daily measurements of eosinophils.

the most commonly used treatment for acute exacerbations of chronic obstructive pulmonary disease (aecopd) is a 5-day treatment with corticosteroids in moderate-high dose. some patients receive repeated treatments, although it has been shown that corticosteroids only have temporary beneficial effects and no effect in relation to serious incidents or mortality. it has been found that the higher accumulated prednisolone dose disables patients due to serious side effects, including pneumonia, dysregulated diabetes, bone fracture in the context of osteoporosis, mental disorder and adrenal insufficiency etc. however, the extent of the side effects is unknown. recent research has shown that it is presumably only a small subset of copd patients who benefit from corticosteroid therapy. this group can be identified by the biomarker "blood-eosinophils" as already measured on most aecopd patients during hospitalization. this is a randomized, controlled, multi-center, non-inferiority trial evaluating the effect of eosinophil guided corticosteroid therapy to patients with aecopd. the aim of the study is to investigate whether the accumulated dose corticosteroid treatment during admissions for aecopd can be reduced, including the presumed side effects, while (still) remaining the optimal treatment effect.

Eligibility criteria:
inclusion criteria: * patients hospitalized with aecopd * age ≥ 40 years * spirometry-verified copd (defined as fev1 / fvc ≤ 70%) * chronic obstructive lung disease (gold) class c or d * inclusion within 24 hours after admission exclusion criteria: * known with a diagnosis of asthma * life expectancy less than 30 days * serious exacerbation requiring invasive ventilation or admission to icu * allergy to systemic corticosteroids * severe mental illness, which is not controlled by medication * people who are detained under the act on the use of coercion in psychiatry * severe language problems or inability to provide written informed consent * pregnancy and lactation * systemic fungal infections
an open-label, multi-center phase ⅳ trial to evaluate the efficacy and safety of sequential neoadjuvant chemotherapy with docetaxel(monotaxel®) after doxorubicin plus cyclophosphamide combination chemotherapy in locally advanced breast cancer

Conditions: Locally Advanced Breast Cancer

Summary: this is a multicenter, open-label, phase iv trial to assess the efficacy and safety of sequential neoadjuvant chemotherapy with 4 cycles of doxorubicin/cyclophosphamide followed by 4 cycles of docetaxel(monotaxel®) in patients with breast cancer of ≥5cm in size or cytologically confirmed axillary lymph nodes metastasis.


Eligibility criteria:
inclusion criteria: 1. patients with histologically proven invasive breast cancer - the primary tumor size is at least 5cm or cytologically proven axillary node metastasis 2. no evidence of systemic metastasis pathologically or radiologically 3. age at the time of diagnosis between 20 and 70 years 4. patients with previously untreated primary breast cancer including chemotherapy 5. general performance status with ecog 0-2 6. sufficient hematopoietic function (absolute neutrophil count of ≥ 1,500/mm3, platelet count of ≥ 100,000/mm3, and hemoglobin of ≥ 10 g/dl) 7. sufficient renal function (serum creatinine level of ≤ 1.5 mg/dl) 8. sufficient liver function (total serum bilirubin level ≤ 1.5 times the upper normal limit; serum ast and alt levels ≤ 1.5 times the upper normal limit; and serum alkaline phosphatase level ≤ 1.5 times the upper normal limit) 9. sufficient cardiac function (normal electrocardiography within 1 month or lvef\>50% by echocardiography or muga scan within 3 months) 10. patients who agree to enroll this clinical trial and sign the written informed consent voluntarily exclusion criteria: 1. patients with evidence of distant metastases 2. patients with other previous malignancy except breast cancer 3. pregnant (positive hcg test 1 week before registration) or lactating patient 4. uncontrolled serious infection 5. patients with psychiatric disease or epilepsy 6. patients with clinically severe cardiac disease within 6 months such as atrial or ventricular arrhythmia, congestive heart failure, myocardial infarction, or unstable angina 7. male breast cancer 8. patients with poor general condition who are not able to understand or sign the written informed consent
safety and efficacy of xalkori ros1

Conditions: Non-small Cell Lung Cancer

Summary: the objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the lpd (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.


Eligibility criteria:
inclusion criteria: * patients with unresectable progressive/recurrent nsclc who are naive to xalkori and whose tumor is ros1 gene positive exclusion criteria: * patients with past history of hypersensitivity to any of the ingredients of xalkori
genetic risk of osteonecrosis of the jaw (onj) in patients with metastatic cancer

Conditions: Bone Diseases; Metastases; Osteonecrosis; Bisphosphonate-Associated Osteonecrosis of the Jaw

Summary: this study seeks to identify risk factors associated with the development of a jaw condition seen in patients with cancer treated with certain medications.

the goal of this research is to build an index of risk for estimating an individual's risk of developing osteonecrosis of the jaw (onj). the bisphosphonates are an important supportive therapy in the care of patients with metastatic bone disease; they are able to prevent catastrophic events such as fracture and spinal cord compression. however, onj has been associated with the use of the bisphosphonates and onj carries significant morbidity. presently, there are insufficient data to calculate the onj risk benefit ratio of bisphosphonate use. an onj risk assessment tool would improve both the oncologist's and the dental health professional the ability to anticipate and potentially mitigate oral toxicities from bisphosphonate therapy. this protocol consists of a case (onj) control (no onj) study to identify factors associated with the risk of onj and to build an index predictive of an individual's risk of developing onj. the index of onj risk will be comprised of clinical, epidemiologic and genetic factors

Eligibility criteria:
inclusion criteria: * the study candidate must have sufficient formalin fixed paraffin embedded (ffpe)specimens (lymph node or tumor) for dna extraction available for study snp assessment * patients over the age of 21 with a histologically confirmed diagnosis of cancer who have received nitrogen containing bisphosphonate therapy for metastatic bone disease. * ffpe tissues are to have been removed for clinical indication and sufficience study volume of specimen must be available in an established tissue repository. * - study ffpe tissues include: * formalin fixed paraffin embedded leukocytes from lymph nodes with or without involvement by tumor and/or * formalin fixed paraffin embedded tumor tissue (tumor block without invasive cancer is acceptable if the specimen is believed to be sufficiently cellular (breast tissue or noninvasive cancer) to yield adequate dna) * medical records available for data abstraction exclusion criteria: * insufficient specimen available to perform the assays proposed for specimen dna analysis * no accessable medical records

Keywords: osteonecrosis of the jaw (onj)
a strategy to prevent the recurrence of dental disease in children receiving dental treatment with general anesthesia

Conditions: Caries

Summary: the purpose of this study is to evaluate the effectiveness of a preventive strategy in increasing return to follow up and recall appointments.


Eligibility criteria:
inclusion criteria: 1. parent with child (patient) planned for dental treatment with general anesthesia (ga) 2. parent of a child (patient) age less than six 3. parent of a child (patient) with health status of healthy (american society of anesthesiologists (asa) i or ii). exclusion criteria: 1. parents/guardians who chose not to participate in the study 2. parents who spoke a language other than english or spanish 3. parents of a child (patient) with special health care needs or patients of asa iii or iv status
longterm safety study of bema buprenorphine in subjects with chronic low back pain

Conditions: Pain; Low Back Pain

Summary: this is an open label study of up to approximately 52 weeks duration to assess the safety and effectiveness of bema buprenorphine in the management of moderate to severe chronic low back pain. bema buprenorphine is an oral transmucosal form of the opioid analgesic, buprenorphine hydrochloride, intended for application to the buccal mucosa. buprenorphine is a synthetic opioid that is classified as a partial μ-receptor agonist and a schedule iii controlled substance in the united states.


Eligibility criteria:
inclusion criteria: * male or non-pregnant and non-nursing female aged 18 or older * history of moderate to severe chronic low back pain for ≥3 months with a pain intensity ≥5 \[11 point nrs\] reported during screening following discontinuation of current pain medication (opioids and nsaids) and currently taking ≥10 mg oral morphine equivalent/day for ≥2 weeks * stable health, as determined by the investigator, on the basis of medical history, physical examination, and laboratory results so as to comply with all study procedures * female subjects of childbearing potential must be using a recognized effective method of birth control * written informed consent obtained prior to any procedure being performed exclusion criteria: * cancer related pain * reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis * surgical procedure for pain within 2 months, or nerve/plexus block within 4 weeks, prior to titration period day 0/1 visit * history of severe emesis with opioids * clinically significant sleep apnea in the judgment of the investigator

Keywords: buccal soluble film pain back pain low back pain buprenorphine analgesics, opioid analgesics